GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Protalix BioTherapeutics
Protalix is an Israeli biotech company that uses plant cells to produce proteins for the treatment of rare diseases. Its stock price reflects both the innovativeness of its platform and the long and arduous path to FDA approval and commercial success.
Share prices of companies in the market segment - Specialized pharma
Protalix BioTherapeutics is an Israeli biopharmaceutical company that uses its ProCellEx plant cell-based platform to produce recombinant proteins. We classify it as a "Specialty Pharmaceutical" due to its unique technology. The chart below shows the dynamics of this innovative biotech sector.
Broad Market Index - GURU.Markets
Protalix BioTherapeutics is an Israeli biopharmaceutical company that uses its plant-based platform to produce recombinant proteins for the treatment of rare diseases. It is part of the GURU.Markets index and represents the biotech sector. The chart below shows the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
PLX - Daily change in the company's share price Protalix BioTherapeutics
Shares of Protalix, a biopharmaceutical company, exhibit high volatility, as measured by change_co. This reflects sensitivity to FDA decisions and the commercial success of its drugs. This metric is important for biotech sector analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Protalix BioTherapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparing it to PLX, with its unique plant-based protein production platform, helps assess its risk profile.
Daily change in the price of a broad market stock, index - GURU.Markets
Protalix BioTherapeutics uses a unique technology to produce medicinal proteins in plant cells. This Israeli biotech company's shares are driven by news of clinical trials and regulatory approvals, adding an element of high scientific volatility to the overall market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Protalix BioTherapeutics
Protalix BioTherapeutics' year-over-year performance is a story of its unique plant-based platform being applied to drug production. Its market cap growth over the past 12 months reflects the successful approval and launch of its drug for Fabry disease, which represents fundamental validation of its technology and opens up prospects for other developments.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Protalix BioTherapeutics, Inc. is an Israeli biopharmaceutical company with a unique technology for producing recombinant proteins in plant cells. This chart shows how the market views its innovative platform, clinical trial results, and the commercial potential of its products.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Protalix is a biopharmaceutical company whose stock performance is driven by sales success of its drugs for rare diseases and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Protalix BioTherapeutics
Protalix BioTherapeutics uses a unique technology for producing plant-based drugs. Its monthly performance is determined by developments in clinical development and FDA regulatory decisions. Success in trials or approval of a new drug can dramatically change the company's valuation, which is reflected by sharp movements on the chart.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
This chart reflects the dynamics of the biotech sector. For Protalix, with its unique plant-based protein production platform, it's the backdrop. Its movements reflect how clinical trial successes and FDA approvals influence investor sentiment across the industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Protalix BioTherapeutics is an Israeli biopharmaceutical company that uses plant cells to produce recombinant proteins to treat rare diseases. The full market chart allows you to assess how Protalix shares are performing after transitioning from development to commercial growth, and how its unique technology allows it to withstand overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Protalix BioTherapeutics
Protalix BioTherapeutics is an Israeli biopharmaceutical company that uses plant cells to produce recombinant proteins to treat rare diseases. Its weekly stock price is driven by news of drug approvals and sales.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Protalix BioTherapeutics uses plant cells to produce recombinant proteins to treat rare diseases. This unique technology is unique. The chart will show how the market is evaluating this innovative approach: does it allow the company to move faster and more sustainably than traditional biotech companies?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Protalix is a biotech company with an innovative drug manufacturing technology. This chart shows how expectations for this unique technology influence the stock's performance, distinguishing it from the market and creating its own investment profile.
Market capitalization of the company, segment and market as a whole
PLX - Market capitalization of the company Protalix BioTherapeutics
The market capitalization chart of Protalix BioTherapeutics, an Israeli biotech company, reflects its unique platform for producing proteins in plant cells. Its volatile chart reflects how investors view the approval of its first drug and the potential of its technology for developing other treatments for rare diseases.
PLX - Share of the company's market capitalization Protalix BioTherapeutics within the market segment - Specialized pharma
Protalix BioTherapeutics is an Israeli biotech company that uses a unique plant cell-based platform to produce recombinant proteins to treat rare diseases. Its market share is small. The chart illustrates the complex path this innovative technology has taken to commercial success.
Market capitalization of the market segment - Specialized pharma
Here's a chart showing the biotech sector's market capitalization. Protalix BioTherapeutics is an Israeli company that uses a unique plant cell-based platform to produce proteins. Its market history exemplifies how innovative manufacturing technology can become a competitive advantage in developing drugs for rare diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Protalix BioTherapeutics uses unique plant cell-based technology to produce recombinant proteins for the treatment of rare diseases. Its market capitalization is a bet on this platform. The chart below shows the economic weight of innovative manufacturing technologies.
Book value capitalization of the company, segment and market as a whole
PLX - Book value capitalization of the company Protalix BioTherapeutics
Protalix's foundation is its unique ProCellEx® biotech platform for producing recombinant proteins in plant cells and its approved drugs. This chart tells the story of the company, which is using its innovative and cost-effective manufacturing technology to create drugs for rare diseases.
PLX - Share of the company's book capitalization Protalix BioTherapeutics within the market segment - Specialized pharma
Protalix BioTherapeutics uses plant cells to produce proteins. The chart shows its share of real assets. This is its unique plant, where drugs for rare diseases are produced in bioreactors using carrot cells.
Market segment balance sheet capitalization - Specialized pharma
Protalix, a biopharmaceutical company with a unique manufacturing platform, is more capital-intensive than R&D startups. The chart below illustrates the scale of the pharmaceutical sector, providing context for assessing its integrated model.
Book value of all companies included in the broad market index - GURU.Markets
Protalix BioTherapeutics uses plant cells to produce recombinant proteins to treat rare diseases. The company's assets include its unique manufacturing platform. Its stake in BCap_All provides the foundation for an innovative and potentially lower-cost method for producing complex drugs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Protalix BioTherapeutics
Protalix BioTherapeutics is an Israeli biopharmaceutical company. The company's valuation reflects its unique platform for producing proteins in plant cells and its FDA-approved drug for the treatment of Fabry disease.
Market to book capitalization ratio in a market segment - Specialized pharma
Protalix BioTherapeutics uses plant cells to produce recombinant proteins to treat rare diseases. The company's value lies in its unique production platform. The chart shows the premium investors are paying for this innovative technology.
Market to book capitalization ratio for the market as a whole
Protalix BioTherapeutics is an Israeli biotech company that uses plant cells to produce proteins for drugs. It offers a unique production platform. This chart shows the market premium the company is willing to pay for innovative pharmaceutical manufacturing technologies that can reduce costs.
Debts of the company, segment and market as a whole
PLX - Company debts Protalix BioTherapeutics
Protalix BioTherapeutics, a biopharmaceutical company using a unique technology to produce proteins in plant cells, is raising capital to finance its development. The debt burden reflects the cost of conducting clinical trials and bringing drugs to market for rare genetic diseases such as Fabry disease.
Market segment debts - Specialized pharma
Protalix BioTherapeutics uses a unique plant cell-based technology to produce recombinant proteins to treat rare diseases. This is an innovative yet capital-intensive approach in biopharmaceuticals. This chart shows how the company funds its research and production using its proprietary platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Protalix BioTherapeutics
Protalix BioTherapeutics uses plant cells to produce proteins to treat rare diseases. This unique technology requires investment in R&D and production. This chart shows the company's reliance on debt to finance its operations, which is an important indicator of its financial health as it seeks profitability.
Market segment debt to market segment book capitalization - Specialized pharma
Protalix BioTherapeutics is an Israeli biotech company that uses plant cells to produce recombinant therapeutic proteins. This chart shows debt trends in their sector, helping to assess how the company finances its unique manufacturing platform and the commercialization of drugs for rare diseases.
Debt to book value of all companies in the market
Protalix BioTherapeutics is a biopharmaceutical company that uses plant cells to produce proteins for therapeutic purposes. Despite having approved products, funding new developments remains a key challenge. This chart helps assess whether the company is leveraging revenue and debt for growth, like a mature company, or whether it still relies heavily on equity capital to fund R&D.
P/E of the company, segment and market as a whole
P/E - Protalix BioTherapeutics
Protalix BioTherapeutics is an Israeli biopharmaceutical company that uses plant cells to produce recombinant proteins to treat rare diseases. This chart shows how the market values its unique production platform. This value depends on the success of its drugs and the potential of its technology.
P/E of the market segment - Specialized pharma
This chart shows the average valuation for biopharmaceutical companies, providing context for Protalix. It reflects overall sentiment in the sector. Comparisons with this valuation help understand how the market values Protalix's unique plant-based protein production technology and its portfolio of rare disease treatments.
P/E of the market as a whole
Protalix BioTherapeutics is an Israeli company that uses plant cells to produce recombinant proteins to treat rare diseases. It offers a unique production platform. This chart of overall biotech risk appetite shows how confident investors are in the advantages of this technology over traditional manufacturing methods.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Protalix BioTherapeutics
Protalix BioTherapeutics is an Israeli biopharmaceutical company that uses plant cells to produce recombinant therapeutic proteins. This chart shows the expected value of its unique production platform. This estimate depends on the commercial success of its approved drugs and progress in the clinical development of other candidates for rare diseases.
%20P%2FE%20Protalix%20BioTherapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Protalix-BioTherapeutics&v=1772547526905 "Chart of the company's future (projected) P/E Protalix BioTherapeutics")
Future (projected) P/E of the market segment - Specialized pharma
Protalix BioTherapeutics is a biopharmaceutical company using its proprietary plant cell expression system to develop recombinant therapeutic proteins. This chart reflects investor expectations for the company's profitability relative to the sector, allowing for an assessment of how the market views its unique manufacturing platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772547526916 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Protalix BioTherapeutics is an Israeli biopharmaceutical company that uses plant cells to produce recombinant proteins to treat rare diseases. Against the backdrop of overall market expectations, as illustrated by this chart, Protalix's business is driven by scientific and regulatory successes, as well as partnerships with major pharmaceutical companies to commercialize their products.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772547526973 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Protalix BioTherapeutics
Protalix BioTherapeutics is an Israeli company that has developed a unique technology for producing recombinant proteins in plant cells. This chart shows the financial results of the company, which uses this innovative platform to develop drugs for rare diseases.
Profit of companies in the market segment - Specialized pharma
Protalix BioTherapeutics uses its unique plant-based ProCellEx platform to produce recombinant therapeutic proteins. This chart shows profitability in the specialty pharmaceuticals sector. For PLX, this reflects the potential of their innovative technology to create complex drugs for rare diseases like Gaucher disease.
Overall market profit
Protalix BioTherapeutics is an Israeli biotechnology company that uses a unique plant cell-based platform to produce recombinant proteins. Its drugs are designed to treat rare genetic diseases. The company's success depends on its scientific platform. This graph does not reflect the potential of such innovative technologies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Protalix BioTherapeutics
Protalix BioTherapeutics is an Israeli biotechnology company that uses plant cells to produce recombinant therapeutic proteins. The revenue projections presented here are dependent on the commercial success of its approved drug for Fabry disease and the progress of its other developments.
%20profit%20of%20the%20company%20Protalix%20BioTherapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Protalix-BioTherapeutics&v=1772547527322 "Graph of future (projected) profit of the company Protalix BioTherapeutics")
Future (predicted) profit of companies in the market segment - Specialized pharma
Protalix BioTherapeutics uses plant cells to produce recombinant therapeutic proteins for the treatment of rare diseases. The profit forecast for this sector depends on the success of this innovative production platform. This chart reflects analysts' confidence in the potential of plant biotechnology as an alternative to traditional methods.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772547527387 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Protalix BioTherapeutics is an Israeli biopharmaceutical company that uses plant cells to produce recombinant proteins to treat rare diseases. Its success depends on the approval and commercialization of its drugs. The profit projections presented here influence the overall investment climate in biotech.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772547527485 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Protalix BioTherapeutics
Protalix BioTherapeutics is an Israeli company that uses plant cells to produce recombinant therapeutic proteins. This chart shows how the market values its revenue, which consists of royalties and sales of its approved drug for Gaucher disease. This value reflects the potential of its unique manufacturing platform.
P/S market segment - Specialized pharma
Protalix BioTherapeutics is a biopharmaceutical company that has developed a unique platform for producing recombinant proteins in plant cells. This innovative approach is used to develop drugs for rare diseases. This chart shows the average revenue estimate for the sector, helping to understand the premium the market is paying for Protalix's unique technology.
P/S of the market as a whole
Protalix BioTherapeutics is an Israeli biopharmaceutical company that uses its unique plant cell-based platform to produce recombinant proteins to treat rare diseases. This chart provides a general market backdrop for assessing investor sentiment toward innovative but risky biotech companies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Protalix BioTherapeutics
Protalix BioTherapeutics is a biopharmaceutical company that uses plant cells to produce recombinant therapeutic proteins. This chart shows how investors estimate the company's future revenue, reflecting the potential of its unique manufacturing platform.
%20P%2FS%20Protalix%20BioTherapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Protalix-BioTherapeutics&v=1772547527792 "The graph of the company's future (projected) P/S Protalix BioTherapeutics")
Future (projected) P/S of the market segment - Specialized pharma
Protalix BioTherapeutics is a biopharmaceutical company that uses plant cells to produce recombinant therapeutic proteins. It offers a unique manufacturing platform. This chart reflects how the market views its innovative technology and its portfolio of rare disease treatments.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772547527806 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Protalix BioTherapeutics is an Israeli biopharmaceutical company that uses plant cells to produce proteins for the treatment of rare diseases. Their success depends on the approval and commercialization of their drugs. This market optimism curve is important, as it impacts the availability of capital to finance their unique and risky manufacturing platform.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772547527875 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Protalix BioTherapeutics
Protalix BioTherapeutics is a biopharmaceutical company that has developed a unique technology for producing recombinant proteins in plant cells. The company has approved drugs. This chart shows sales revenue and royalties. Revenue growth depends on demand for its drugs for rare diseases, such as Gaucher disease.
Sales of companies in the market segment - Specialized pharma
Protalix BioTherapeutics is an Israeli biopharmaceutical company that has developed a unique technology for producing therapeutic proteins in plant cells. They have an approved drug for the treatment of Gaucher disease. Their revenue is generated through sales of this drug and licensing agreements with partners.
Overall market sales
Protalix BioTherapeutics is an Israeli biopharmaceutical company that has developed a unique technology for producing recombinant proteins in plant cells. This approach enables the creation of complex drugs for the treatment of rare diseases. This total revenue chart includes the healthcare sector, where PLX exemplifies technological innovation in pharmaceuticals.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Protalix BioTherapeutics
Protalix BioTherapeutics is an Israeli company that uses plant cells to produce recombinant proteins to treat rare diseases such as Gaucher and Fabry disease. This chart shows the expected sales of its approved drugs and the success of its new developments.
%20sales%20of%20the%20company%20Protalix%20BioTherapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Protalix-BioTherapeutics&v=1772547528056 "Schedule of future (projected) sales of the company Protalix BioTherapeutics")
Future (projected) sales of companies in the market segment - Specialized pharma
Protalix BioTherapeutics uses its unique plant cell-based technology to produce recombinant therapeutic proteins for the treatment of rare diseases. This chart shows forecasts for the orphan drug market, highlighting the potential of innovative manufacturing platforms to create more effective and affordable medicines.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772547528202 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Protalix BioTherapeutics, a biotech company that uses plant cells to produce proteins, sees this chart as a reflection of demand for innovative treatments for rare diseases. The robust economic growth projected here allows healthcare systems to finance expensive drugs like those being developed by Protalix.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772547528281 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Protalix BioTherapeutics
Protalix BioTherapeutics is a biopharmaceutical company using its unique plant-based platform, ProCellEx, to develop proteins for the treatment of rare diseases. Its financial indicators reflect both revenue from approved drugs and R&D expenses. This chart shows the balance between commercialization and investment in innovation.
Market segment marginality - Specialized pharma
Protalix BioTherapeutics uses its unique plant-based ProCellEx platform to develop and produce recombinant therapeutic proteins. This indicator reflects the commercial success of its technology. This high result speaks to the effectiveness of its production system and the demand for its products.
Market marginality as a whole
Protalix BioTherapeutics is an Israeli biopharmaceutical company with a unique platform for producing proteins in plant cells. Its success depends on the approval and commercialization of its drugs for the treatment of rare diseases. This gross profit chart has no bearing on Protalix's scientific and regulatory trajectory.
Employees in the company, segment and market as a whole
Number of employees in the company Protalix BioTherapeutics
Protalix BioTherapeutics is an Israeli biopharmaceutical company that uses its unique plant cell-based platform to produce recombinant proteins. This graphic shows the team of scientists developing and producing enzyme replacement therapies for rare genetic diseases such as Fabry disease.
Share of the company's employees Protalix BioTherapeutics within the market segment - Specialized pharma
Protalix BioTherapeutics is a biopharmaceutical company using its unique plant cell-based ProCellEx technology to produce recombinant therapeutic proteins. This innovative manufacturing platform requires a unique team of specialists. This chart illustrates the concentration of talent needed to develop this new technology.
Number of employees in the market segment - Specialized pharma
Protalix BioTherapeutics is an Israeli biotech company that uses a unique technology to produce recombinant proteins in plant (carrot) cells to treat rare diseases. This graph shows the team of scientists who have developed an innovative and potentially more cost-effective platform for creating complex biological drugs.
Number of employees in the market as a whole
Protalix BioTherapeutics is an Israeli company developing plant-cell-based protein therapeutics. Their innovative technology requires significant investment. The overall economic environment, reflected in the employment chart, provides the backdrop for such funding. A stable market attracts capital to cutting-edge biotech, allowing Protalix to develop its unique platform.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Protalix BioTherapeutics (PLX)
Protalix BioTherapeutics is an Israeli company that uses plant cells to produce proteins for drugs. This chart is a testament to their unique manufacturing platform. Their high market capitalization per employee reflects the potential of their technology to produce complex drugs more efficiently than traditional methods.
%20of%20the%20company%20Protalix%20BioTherapeutics%20(PLX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Protalix-BioTherapeutics-PLX&v=1772547528881 "Chart of market capitalization per employee (in thousands of dollars) of the company Protalix BioTherapeutics (PLX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Protalix BioTherapeutics is a biopharmaceutical company that uses plant cells to produce recombinant therapeutic proteins. Its value is based on its unique manufacturing platform. This chart shows how the market values its innovative technology per employee compared to other biotech companies.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772547528884 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Protalix BioTherapeutics is an Israeli biotechnology company that uses plant cells to produce recombinant therapeutic proteins. This metric reflects the potential of its unique production platform and demonstrates how the market perceives its ability to create complex drugs more efficiently.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772547528921 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Protalix BioTherapeutics (PLX)
Protalix is an Israeli biotech company that uses plant cells (carrots) to produce proteins for drugs (for example, for Gaucher disease). This chart shows how their unique production platform is being commercialized. Their R&D and manufacturing teams are creating a high-margin product.
%20Chart%20Protalix%20BioTherapeutics%20(PLX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Protalix-BioTherapeutics-PLX&v=1772547528982 "Company Profit Per Employee (in thousands of dollars) Chart Protalix BioTherapeutics (PLX)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Protalix BioTherapeutics (PLX) is a biotechnology company using the unique ProCellEx platform (based on plant cells) to produce recombinant proteins for the treatment of rare diseases (such as Gaucher disease). This chart represents an industry benchmark and reflects how successfully Protalix is leveraging its innovative manufacturing platform to develop and commercialize orphan drugs.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772547529016 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Protalix BioTherapeutics (PLX) is an Israeli biotech company with a unique platform (ProCellEx). They use carrot cells in bioreactors to produce human proteins (drugs), such as those for Gaucher disease. This process combines R&D and manufacturing. This graph shows how successfully their team can commercialize this unique drug production technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772547529046 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Protalix BioTherapeutics (PLX)
Protalix BioTherapeutics is an Israeli biotech company that uses plant cells to produce therapeutic proteins. This chart shows the commercialization of its unique production platform. The growth in revenue per employee reflects sales of its approved Gaucher disease drug and the potential for other drugs in development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Protalix-BioTherapeutics-PLX&v=1772547529068 "Sales chart per company employee Protalix BioTherapeutics (PLX)")
Sales per employee in the market segment - Specialized pharma
Protalix (PLX) is an Israeli biotech company with a unique technology for producing proteins in plant cells (ProCellEx). They have an approved drug for Gaucher disease. This chart shows how effective their unique R&D and manufacturing platform is in generating revenue per employee compared to traditional pharmaceuticals.
Sales per employee for the market as a whole
Protalix is an Israeli biotech company with a unique platform, ProCellEx. They use plant cells (carrots) in bioreactors to produce complex protein drugs (for example, for Gaucher disease). This graph shows how much revenue their R&D team generates from sales and partnerships.
Short shares by company, segment and market as a whole
Shares shorted by company Protalix BioTherapeutics (PLX)
Protalix (PLX) is an Israeli biotech company that uses the unique ProCellEx platform (based on plant cells) to produce recombinant proteins to treat rare diseases. This chart shows bearish bets. The rise in shorts may reflect investor doubts about the commercial success of their approved drugs or the effectiveness of their plant-based platform.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Protalix-BioTherapeutics-PLX&v=1772547529166 "Short Shares Chart for the Company Protalix BioTherapeutics (PLX)")
Shares shorted by market segment - Specialized pharma
Protalix (PLX) is an Israeli biotech company that uses plant cells (ProCellEx) to produce recombinant proteins to treat rare diseases. This chart illustrates the general skepticism in the biotech sector, reflecting investor doubts about the commercial success of this unique production platform.
Shares shorted by the overall market
Protalix (PLX) is a biotech company using plant cells to produce drugs. It's a unique, yet speculative, R&D platform. When this market fear indicator rises, investors are unwilling to fund R&D. They sell off unprofitable biotechs like PLX en masse, fearing they'll run out of cash.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Protalix BioTherapeutics (PLX)
Protalix BioTherapeutics develops protein therapies using plant cells. The stock is speculative and dependent on R&D. This chart can soar above 70 on positive trial data or FDA approvals. Oversold territory (<30) often reflects setbacks, delays, or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Protalix-BioTherapeutics-PLX&v=1772547529259 "RSI 14 indicator chart for the company's stock Protalix BioTherapeutics (PLX)")
RSI 14 Market Segment - Specialized pharma
Protalix (PLX) is "carrot biotech." This Israeli company uses *plant cells* to *produce* complex protein drugs (for Gaucher disease). The RSI_14_Seg for "Specialized pharma" (biotech) shows the overall sentiment. It helps us understand: is PLX's volatility due to its R&D or is the *entire* sector "overheated"?
RSI 14 for the overall market
Protalix (PLX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PLX (Protalix BioTherapeutics)
Protalix (PLX) is an Israeli biopharmaceutical company that uses plant cells to produce recombinant proteins to treat rare diseases (such as Gaucher disease). This chart shows the average target price, reflecting analysts' opinions on the commercial success of its drugs and this unique technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PLX-Protalix-BioTherapeutics&v=1772547529486 "A chart showing analyst consensus forecasts for the expected stock price. PLX (Protalix BioTherapeutics)")
The difference between the consensus estimate and the actual stock price PLX (Protalix BioTherapeutics)
Protalix is an Israeli biotech company that uses the unique ProCellEx platform (based on carrot cells) to produce proteins for the treatment of rare diseases. This chart measures the gap between the current price and the consensus target price. It shows whether experts believe their Fabry disease drug will be commercially successful.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PLX-Protalix-BioTherapeutics&v=1772547529520 "A chart showing the difference between the consensus forecast and the actual stock price. PLX (Protalix BioTherapeutics)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Protalix BioTherapeutics is an Israeli biotech company that uses plant cells (carrots) to produce recombinant proteins to treat rare diseases (such as Gaucher disease). This chart shows the overall expectations for the specialty pharmaceutical sector and reflects the confidence of experts in this unique production platform.
Analysts' consensus forecast for the overall market share price
Protalix (PLX) is an Israeli biotech company with a unique platform: they use plant cells (carrots) in bioreactors to produce complex protein drugs (for example, for Gaucher disease). This chart shows overall market sentiment. For Protalix, with their innovative R&D platform, it's important to consider how risk appetite (sentiment) influences their valuation. (350)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Protalix BioTherapeutics
Protalix BioTherapeutics is an Israeli biotech company with a unique facility: they use genetically modified carrot cells in bioreactors to produce complex protein drugs for rare diseases. This graph is an assessment of their unique R&D platform. It reflects the commercial success of their approved drug and the potential of their plant-based production system.
AKIMA Market Segment Index - Specialized pharma
Protalix BioTherapeutics is an Israeli company that uses plant cells (ProCellEx technology) to produce recombinant proteins for the treatment of rare diseases, such as Gaucher disease. This chart shows the average index for the pharmaceutical sector. It allows one to assess how Protalix's innovative production platform compares to the industry average.
The AKIM Index for the overall market
Protalix is a biotech company that uses plant cells to produce recombinant proteins (for Fabry disease). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this technology platform with an approved drug compares to overall economic trends in the rare disease sector.
